Investor Relations

Our Goal – Confidence and Common Success

It is our firm wish to maintain an open and honest relationship between potential investors, share holders and Bachem. We inform transparently and consequently about all relevant facts; according to our internal guidelines and all statutory laws and guidelines. Investor Relations has to prepare and provide this information in a timely, correct and meaningful manner. We want to ensure that our shareholders and potential investors get a reliable picture of the Bachem Group in terms of the current situation and expected future developments. We aim to achieve a basis of trust on which we can build and maintain long term and successful relationships. We are looking forward to working with you.

In Dialog with Bachem

We stay in contact and dialog with our investors through the following channels:

• Our annual general meeting
• Our half-year and annual report
• Press and media releases
• Visits at our site in Bubendorf
• Roadshows and investor relations events
• Individual contacts, personally or by phone

About Bachem

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.